Herishanu Yair, Polliack Aaron, Leider-Trejo Leonor, Grieff Yoel, Metser Ur, Naparstek Elizabeth
Department of Hematology , Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel.
Clin Lymphoma Myeloma. 2006 Mar;6(5):407-9. doi: 10.3816/CLM.2006.n.019.
Rituximab, a chimeric anti-CD20 monoclonal antibody, is commonly being used to treat indolent and aggressive B-cell non-Hodgkin's lymphoma. Rituximab is considered a relatively safe drug, but recently, severe and fatal adverse effects related to this drug have been reported. In this regard, we report an 80-year-old patient with follicular grade 3 non-Hodgkin's lymphoma who developed a fatal interstitial pneumonitis related to treatment with a rituximab/CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen. The pneumonitis was diagnosed on a routine midtreatment positron emission tomography/computed tomography scan when the patient was almost asymptomatic. Pulmonary deterioration occurred as the treatment with rituximab/CHOP was continued. In this article, we also review the literature on rituximab-associated pneumonitis, and we discuss the differential diagnosis with cyclophosphamide-induced lung injury.
利妥昔单抗是一种嵌合抗CD20单克隆抗体，常用于治疗惰性和侵袭性B细胞非霍奇金淋巴瘤。利妥昔单抗被认为是一种相对安全的药物，但最近，与该药物相关的严重和致命不良反应已有报道。在这方面，我们报告了一名80岁的滤泡3级非霍奇金淋巴瘤患者，其因接受利妥昔单抗/CHOP（环磷酰胺/阿霉素/长春新碱/泼尼松）方案治疗而发生致命性间质性肺炎。该肺炎在患者几乎无症状时的常规治疗中期正电子发射断层扫描/计算机断层扫描中被诊断出来。随着利妥昔单抗/CHOP治疗的继续，肺部情况恶化。在本文中，我们还回顾了关于利妥昔单抗相关性肺炎的文献，并讨论了与环磷酰胺所致肺损伤的鉴别诊断。
